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009 Focused Updates to Guidelines in
T-Elevation Myocardial Infarction and
ercutaneous Coronary Intervention
pplication to Interventional Cardiology
on C. George, MD,* George D. Dangas, MD, PHD†
rown Mills, New Jersey; and New York, New York
ractice guidelines reﬂect a consensus of expert opinion for patient care after a thorough review of
linical trials relevant to a given patient population. However, in keeping pace with the inﬂux of new
ata, these recommendations need to be revised periodically to remain current. The American College
f Cardiology (ACC) and the American Heart Association (AHA) published the Guidelines for the Man-
gement of Patients With ST-Elevation Myocardial Infarction in 2004 and the Guidelines for Percutaneous
oronary Intervention in 2005 with their respective Focused Updates in 2007. Now, 2 years later, further
evision of these guidelines has been published as Focused Updates of 2009. (J Am Coll Cardiol Intv 2010;
























ihe ACC and the AHA published the Guidelines for
he Management of Patients With ST-Elevation Myo-
ardial Infarction (STEMI) in 2004 (1) and the Guide-
ines for Percutaneous Coronary Intervention (PCI) in
005 (2). Subsequent clinical trial data prompted their
espective focused updates in 2007 (3,4). Again, based
n key clinical trials presented at the 2007 and 2008
nnual scientific meetings of the ACC, AHA, Trans-
atheter Cardiovascular Therapeutics, European Society
f Cardiology, and the 2009 annual scientific sessions of
he ACC, the ACC/AHA Task Force on Practice
uidelines presented the 2009 Focused Updates of
hese guidelines (5). The revisions pertinent to inter-
entional cardiology are reviewed here.
se of Glycoprotein IIb/IIIa
eceptor Antagonists
n the BRAVE-3 (Bavarian Reperfusion Alternatives
valuation) study, patients presenting within 24 h
rom the *Division of Cardiovascular Medicine, Deborah Heart and
ung Center, Browns Mills, New Jersey; and the †ACC Interventional
cientific Council, Columbia University, New York, New York. Dr.
angas has received speaker honoraria from Sanofi-Aventis, Bristol-
yers Squibb, AstraZeneca, Boston Scientific, Medtronic, Cordis/J&J,d
nd Abbott; is a consultant for Eli Lilly; and is on the scientific advisory
oard of Accumetrics.f STEMI were pretreated with clopidogrel 600 mg
nd then randomly assigned to receive either abcix-
mab or placebo before being sent for PCI (6). At 30
ays, the composite of death, recurrent myocardial
nfarction (MI), stroke, or urgent target vessel revas-
ularization (TVR) was not significantly different
etween the glycoprotein (GP) IIb/IIIa receptor an-
agonist and placebo groups. In the On-TIME 2
Ongoing Tirofiban In Myocardial Infarction
valuation) study, patients were randomized to
igh-dose tirofiban or placebo in addition to un-
ractionated heparin (UFH) and clopidogrel within
median of 76 min from onset of symptoms (7).
lthough the tirofiban group had improved ST-
egment resolution before and 1 h after PCI, there
as no significant difference in death, recurrent
I, or urgent TVR between the 2 groups at 30
ays. In the FINESSE (Facilitated Intervention
ith Enhanced Reperfusion Speed to Stop Events)
tudy, patients with STEMI were randomized to
alf-dose fibrinolytic agent plus abciximab, pre-
CI abciximab, and abciximab at the time of PCI
8). After 90 days, there was no benefit and a trend
oward excess bleeding with pre-hospital abcix-
mab compared with abciximab at the time of PCI.
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257lass IIa: It is reasonable to start treatment with GP
Ib/IIIa receptor antagonists at the time of primary PCI in
elected patients with STEMI.
lass IIb: The usefulness of GP IIb/IIIa receptor antago-
ists for patients with STEMI before their arrival in the
atheterization laboratory for PCI is uncertain.
se of Thienopyridines
he TRITON–TIMI 38 (Trial to Assess Improvement in
herapeutic Outcomes by Optimizing Platelet Inhibition
ith Prasugrel–Thrombolysis In Myocardial Infarction 38)
rial randomly assigned patients with acute coronary syn-
rome treated with angioplasty and stent to receive prasug-
el (60-mg loading dose and a 10-mg/day maintenance
ose) or clopidogrel (300-mg loading dose and a 75-mg/day
aintenance dose) for an average of 14.5 months (9).
rasugrel was associated with a significant reduction of stent
hrombosis and of the composite of the rate of death due to
ardiovascular causes, nonfatal MI, and nonfatal stroke.
Based on these findings, the 2009 Focused Update
ecommends:
lass I: A loading dose of 300- to 600-mg clopidogrel or
0-mg prasugrel should be given as soon as possible for
TEMI patients for whom PCI is planned. The duration of
herapy should be 75-mg clopidogrel or 10-mg prasugrel for
t least 12 months in patients receiving a bare-metal stent
BMS) or drug-eluting stent (DES). The period of with-
rawal of thienopyridine before coronary artery bypass
rafting should be at least 5 days for clopidogrel and at least
days for prasugrel.
lass IIb: Continuation of clopidogrel or prasugrel beyond
5 months may be considered in patients undergoing DES
lacement.
se of Parenteral Anticoagulants
n the HORIZONS-AMI (Harmonizing Outcomes With
evascularization and Stents in Acute Myocardial
nfarction) trial, patients were randomized to treatment
ith UFH plus a GP IIb/IIIa receptor antagonist or to
ivalirudin alone with provisional GP IIb/IIIa in addition to
spirin and a thienopyridine in both groups before cardiac
atheterization and primary angioplasty (10). At 30 days,
he rates of major bleeding and total adverse events were
igher among patients treated with GP IIb/IIIa receptor
ntagonists and UFH than among those given bivalirudin
lone. These data have included an all-cause survival advan-
age with bivalirudin.
Based on these findings, the 2009 Focused Update
ecommends:
lass I: For previous treatment with UFH, additional
oluses of UFH should be administered as needed to
aintain therapeutic activated clotting time levels. Bivaliru- lin is useful as a supportive measure for primary PCI with
r without previous treatment with UFH.
lass IIa: In STEMI patients undergoing PCI who are
t high risk of bleeding, bivalirudin anticoagulation is
easonable.
hrombus Aspiration During PCI
he TAPAS (Thrombus Aspiration During Percutaneous
oronary Intervention in Acute Myocardial Infarction
tudy) randomized STEMI patients to manual thrombus
spiration before PCI or conventional PCI with balloon
ngioplasty followed by stenting (11). At 1 year, the rates of
ardiac death and nonfatal reinfarction were lower with
hrombus aspiration. The EXPIRA (Thrombectomy With
xport Catheter in Infarct-Related Artery During Primary
ercutaneous Coronary Intervention) trial compared
hrombus aspiration with conventional PCI in patients with
hrombolysis in myocardial infarction flow 0/1 and found
hat infarct size was significantly reduced at 3 months only
n the thrombus aspiration group (12).
Based on these studies, the 2009 Focused Update
ecommends:
lass IIa: Aspiration thrombectomy is reasonable for
atients undergoing primary PCI.
tents in STEMI
he randomized trial HORIZONS-AMI showed no dif-
erence in 12-month death, reinfarction, stroke, or stent
hrombosis between DES and BMS (13). Two-year data
rom the Massachusetts registry comparing matched pairs of
ES and BMS patients demonstrated a reduction in
ortality and TVR rates with DES in primary PCI (14).
nother registry from New York State found a reduction in
he mortality rate but not the TVR rate with DES (15).
eta-analyses of multiple small randomized clinical trials
ave shown no differences between BMS and DES in
ortality rate, MI rate, or stent thrombosis risk (16–18).
Based on these studies, the 2009 Focused Update
ecommends:
lass IIa: It is reasonable to use a DES as an alternative to
BMS for primary PCI in STEMI.
lass IIb: A DES may be considered for clinical and
natomic settings in which the efficacy/safety profile seems
avorable.
se of Fractional Flow Reserve
he FAME (Fractional Flow Reserve Versus Angiography
or Guiding PCI in Patients With Multivessel Coronary
rtery Disease) trial compared clinical outcomes after PCI
n the basis of conventional angiographic determination of
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258ined with angiography in patients with multivessel disease
19). At 1 year, the composite event rate of death, nonfatal
I, and TVR was significantly lower in the FFR-guided
roup.
Based on this study, the 2009 Focused Update
ecommends:
lass IIa: FFR can be useful to determine whether PCI of
specific coronary lesion is warranted. FFR can also be
seful as an alternative to performing noninvasive functional
esting to determine whether intervention is warranted.
FR is reasonable for the assessment of intermediate coro-
ary stenoses in patients with anginal symptoms.
lass III: Routine assessment with FFR or Doppler ultra-
onography to assess severity of angiographic disease in
atients with angina and a positive unequivocal noninvasive
unctional study in concordant vascular distribution is not
ecommended.
CI for Unprotected Left Main
oronary Artery Disease
he SYNTAX (TAXUS Drug-Eluting Stent Versus Cor-
nary Artery Bypass Surgery for the Treatment of Narrowed
rteries) clinical trial randomized patients with 3-vessel
nd/or left main coronary artery disease to an initial treat-
ent strategy of coronary artery bypass graft or PCI (20).
ithin the subgroup of patients with left main coronary
rtery disease, there were no significant differences in the
ncidence of the composite end point of death, MI, stroke,
r TVR between the 2 groups. Although the rates of TVR
ere higher, the rates of stroke were lower in the PCI
roup. A white paper produced under the auspices of the
nterventional Scientific Council addressed this subject
omprehensively (21).
Based on these findings, the 2009 Focused Update
ecommends:
lass IIb: PCI of the left main coronary artery with stents
s an alternative to coronary artery bypass graft may be
onsidered in patients with anatomic conditions that are
ssociated with a low risk of PCI procedural complications
nd clinical conditions that predict an increased risk of
dverse surgical outcomes.
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